Introduction {#Sec1}
============

Uveitis denotes a heterogeneous group of diseases characterized by intraocular inflammation. Among the uveitis subtypes, inflammation most commonly involves the eye's anterior segment (30--60% of all uveitis cases) \[[@CR1]\]. Acute anterior uveitis (AAU) is usually unilateral in its presentation. AAU typically resolves following prompt and adequate ophthalmic care. A delayed diagnosis, however, is associated with an increased risk of potentially severe complications \[[@CR2], [@CR3]\]. The diagnosis of AAU typically requires ophthalmic work-up and is aided by slit-lamp examination. On the other hand, non-ophthalmologist doctors may easily misinterpret AAU as harmless external eye disease, e.g., common infectious conjunctivitis. As a consequence of a false diagnosis, adequate treatment may be delayed. Nevertheless, patients are often primarily admitted to general practitioners lacking access to slit-lamps and other ophthalmic instruments. Consequently, there is a need for a simple diagnostic method to diagnose AAU, thereby preventing delays in diagnosis, treatment, and subsequent complications.

Blood tests to detect inflammation are diagnostic cornerstones in a vast number of medical conditions. In AAU, however, blood analyses lack necessary sensitivity and specificity. On the other hand, diagnostic samples from the eye's aqueous humor or vitreous body necessitate invasive techniques that pose a risk of serious ocular complications. By contrast, tear fluid sampling is non-invasive, harmless, and easily performed with minimal training. Moreover, elevated cytokine levels have been demonstrated in tear fluid of AAU patients \[[@CR3]\]. Accordingly, there is a rationale for investigating the diagnostic potential of tear fluid biomarkers in AAU.

By virtue of advancing proteomic analysis methods, quantification of more than 1.500 tear fluid proteins can potentially be achieved \[[@CR4]\]. Furthermore, in unilateral AAU, tear fluid samples from the healthy eye can serve as control and allow for validation of AAU-associated proteins. The basis for examining tear fluid proteins has been laid in studies of disorders like rosacea, dry eye syndromes, and Graves' disease \[[@CR5]\]. The tear fluid proteome in AAU is less explored, but some data do exist. First, one study assessed tear fluid cytokines and chemokines in uveitis patients \[[@CR3]\]. It did not examine the full tear fluid proteome but instead used a multiplex bead analysis that assayed 21 predefined molecules. The authors concluded there were significant differences in the levels of several cytokine in uveitis patients compared with healthy controls. Secondly, in a conference abstract, Angeles-Han et al. reported results from a pilot study on proteome analysis of tear fluid obtained with Schirmer's strips from children with idiopathic or juvenile idiopathic arthritis (JIA)-associated anterior uveitis \[[@CR6]\]. The investigation detected 1.224 unique protein groups, of which 120 were significantly different from healthy controls. Finally, in a study on tear proteome by Chunky et al., lactoferrin and lipocalin were identified as promising biomarkers for JIA-associated uveitis \[[@CR7]\]. Nevertheless, there are no well-defined tear fluid biomarkers for AAU, let alone a consensus about their diagnostic value.

To assess the potential use of tear fluid for diagnostic purposes in AAU, the current pilot study aimed at exploring whether unilateral AAU is associated with ipsilateral changes in the tear fluid proteome.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

The study included five adult patients diagnosed with unilateral AAU at the Department of Ophthalmology at Oslo University Hospital, Norway. All patients were examined by the same ophthalmologist, and the AAU diagnosis was based on (1) Findings: unilateral anterior chamber cells (obligate) and ipsilateral anterior chamber flare, ciliary injection, and miosis. (2) Symptoms: ocular pain and photophobia. Exclusion criteria were age \< 18 years, pregnancy, bilateral AAU, intermediate-, posterior- or pan-uveitis, AAU secondary to suspected or known infectious disease, presence of any concurrent ocular disease (including dry eye syndrome, conjunctivitis, keratitis, eyelid disease, glaucoma, or neoplastic disease), prior severe ocular trauma, prior ocular surgery, intraocular pressure \< 6 or \> 21 mmHg, use of topical eye medication, use of systemic anti-inflammatory medication, or smoking.

Tear fluid sampling {#Sec4}
-------------------

The research group used a modified version of a previously described protocol for utilizing Schirmer's strips to examine tear fluid proteins \[[@CR4], [@CR5]\]. In brief, one Schirmer's test strip was placed in each eye's inferior fornix without concurrent anesthesia and left for 5 min with eyes closed. The strips were then immediately transferred to microcentrifuge tubes and stored at − 140 °C until analyses. To detect changes in the tear fluid proteome of the AAU eye, the healthy eye served as control.

Protein extraction {#Sec5}
------------------

Protein extraction was performed according to a protocol previously reported by the research group \[[@CR4], [@CR5]\].

Ingenuity Pathway Analysis {#Sec6}
--------------------------

To explore biological function, lists of protein identifiers (UniProt) were uploaded onto the web-delivered application Ingenuity Pathways Analysis (IPA) (QIAGEN N.V., Venlo, Netherlands).

Statistical analysis {#Sec7}
--------------------

The R statistical software (R Development Core Team, R 3.4.2 GUI 1.70 El Capitan build \[7434\]) was used for statistical analyses; a one-sample *t* test was used to compare the AAU eyes with the respective healthy controls.

Results {#Sec8}
=======

Patients {#Sec9}
--------

The patients' clinical data are presented in Table [1](#Tab1){ref-type="table"}. Table 1Patients with unilateral acute anterior uveitis included in the studyPatient 1Patient 2Patient 3Patient 4Patient 5Age (years)2857412577SexMaleMaleFemaleMaleFemaleEthnicityCaucasianCaucasianCaucasianCaucasianCaucasianHLA-B27 statusUnknownHLA-B27 negativeHLA-B27 positive and palmoplantar psoriasisUnknownHLA-B27 positivePrevious episodes of AAUNoNoNoYesNoDuration of symptoms prior to tear fluid sampling (days)110517AC flare (laser flare photometry)47/43/54129/311/3\*AC flare (Sun criteria)§0/+ 2+ 2/0+ 1/0+ 4/0AC cells (Sun criteria)§0/+ 1+ 1/0± /0+ 4/0Corneal precipitates§Non-granularNon-granularNoneNon-granularAC fibrinNoNoNoNoYesAC hypopyonNoNoNoNoNoPosterior synechiaeNoNoNoNoYesCells in anterior vitreousNoNoNoNo\#Decimal visual acuity1.0/1.01.0/1.0−−1.2++/1.5−−1.2++/1.2++CF/1.0−−Intraocular pressure (mmHg)14/1713/710/147/1020/10Schirmer test type 1 (0--40; mm)40/4033/4017/77/730/10Bilateral measurements are presented as right eye/left eye*AAU* acute anterior uveitis, *AC* anterior chamber, *CF* counting fingers\*Measurement not obtained§The standardization of uveitis nomenclature criteria not reported\# Posterior segment not visible

Relative tear fluid protein levels in the diseased eye versus the healthy eye {#Sec10}
-----------------------------------------------------------------------------

Relative protein ratios were calculated for 242 tear fluid proteins present in both the diseased and the healthy eye. Of these nine were at least 1.5-fold increased, and eight were at least 1.5-fold decreased in the diseased eye compared with the healthy control. Apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) was significantly increased in the diseased eye compared with the healthy control (fold change 1.43; *P* = 0.04), whereas transglutaminase 2 (TGM2) was significantly decreased in the diseased eye compared with the healthy control (fold change − 1.21; *P* = 0.03). Table [2](#Tab2){ref-type="table"} summarizes the relative ratios of the top 20 upregulated proteins for each of the five patients. Table 2Top 20 upregulated protein level ratios found in tear fluid of the diseased eye relative to the healthy eye of patients with unilateral acute anterior uveitisPatient 1Patient 2Patient 3Patient 4Patient 5Protein symbol*RR*Protein symbol*RR*Protein symbol*RR*Protein symbol*RR*Protein symbol*RR*SERPINA314.73ZG16B5.62DGKZ9.13KRT328.96FGB5.33CEP1044.32GAPDH3.17SCGB2A16.19PTCHD12.70APOH4.87RARRES13.29LTF2.89PLA2G2A6.04EEF1A12.55OPRPN3.85ALDH3A12.85DCD2.86SCGB1D14.19TPI12.33A2M3.79ADIRF2.68OPRPN2.70WWC33.64ADIRF1.96C4A/C4B2.57KRT102.59S100P2.46LYZ3.58S100A111.95WWC32.49CST12.46GSN2.12OPRPN3.35GSTP11.91HPR2.33FABP52.20SCGB1D11.98PSME22.65SCGB1D11.88C32.17ADH72.19EEF1A11.88CST12.54ANXA21.83APOA12.05CP2.06AZGP11.82LACRT2.35LDHA1.68ORM22.00TMSB10/TMSB4X1.76TXN1.80MASP12.27IL1RN1.64A1BG1.81IL1RN1.75PIP1.79B2M2.03GPI1.62HPX1.62RPLP11.70WWC31.69A1BG1.91PSME21.62TF1.50SFN1.70LCN11.52LCN11.76IGHG21.60PIP1.48SH3BGRL1.63LYZ1.43LTF1.75APOBEC3A1.59CLU1.45WFDC21.57ALB1.22S100A61.73B2M1.58DMBT11.44CTIF1.55C31.16HPX1.71FGG1.58CST11.40DBI1.53PKM1.14CST41.67CFL11.53SERPINA31.34YWHAE1.50ACTB1.13LGALS31.67SERPINB11.50IGHG21.33ACTN41.49CLU1.12PIP1.66ATG9A1.50PFN11.25*RR* relative ratio of protein level in tear fluid of diseased versus healthy eye

Thirty-two tear fluid proteins were identified in all five patients; the number of matching proteins was highest between patients 1, 3, and 4 (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Venn diagram illustrating the number and distribution of matching tear fluid proteins in five patients with acute anterior uveitis \[[@CR8]\]

Ingenuity Pathway Analysis {#Sec11}
--------------------------

For all patients, IPA identified the liver X receptor/retinoid X receptor (LXR/RXR) and the farnesoid X receptor/retinoid X receptor (FXR/RXR) among the "Top Canonical Pathways" affected in the tear fluid (Table [3](#Tab3){ref-type="table"}). Table 3Top canonical pathwaysPatient 1Patient 2Patient 3Patient 4Patient 5Protein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueLXR/RXR activation2.04E−12Glycolysis I2.06E−07LXR/RXR activation3.14E−15LXR/RXR activation3.11E−18LXR/RXR activation2.92E−19Glycolysis I3.13E−11LXR/RXR activation1.02E−04FXR/RXR activation1.69E−13Acute phase response signaling5.67E−16FXR/RXR activation2.88E−17FXR/RXR activation8.01E−10Clathrin-mediated endocytosis signaling6.79E−04Acute phase response signaling2.32E−09FXR/RXR activation7.25E−15Acute phase response signaling1.53E−15Gluconeogenesis I1.61E−09Gluconeogenesis I1.25E−03Atherosclerosis signaling2.97E−09Glycolysis I1.24E−11Clathrin-mediated endocytosis signaling5.04E−09Acute phase response signaling2.36E−09FXR/RXR activation2.08E−03Clathrin-mediated endocytosis signaling1.06E−08Atherosclerosis signaling3.63E−09Glycolysis I1.01E−08

Upstream regulator analysis in IPA aims to identify transcriptional regulators that can explain the observed changes in the dataset. IPA identified interleukin 6 (IL6) and/or tumor necrosis factor (TNF) as possible upstream regulators in four of the five patients (Table [4](#Tab4){ref-type="table"}). Table 4Top upstream regulatorsPatient 1Patient 2Patient 3Patient 4Patient 5Protein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueMAPT1.32E−24APP5.03E−11MAPT7.78E−15IL61.65E−16MAPT5.83E−12APP1.78E−22MAPT5.49E−11APP6.79E−13APP1.46E−14APP1.72E−11TP533.21E−19PSEN12.71E−09TNF8.03E−13MAPT2.12E−13ZNF1063.96E−11TNF9.00E−19Growth hormone2.87E−07PSEN13.75E−12PCGEM14.90E−12PSEN16.04E−10PSEN11.40E−17MYC7.50E−07IL61.04E−11TNF5.37E−11IL69.72E−10

Furthermore, for all patients IPA recognized "inflammatory response" and "immune cell trafficking" among the top categories within "Diseases and Bio functions" (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). Table 5Top diseases and bio functions---diseases and disordersPatient 1Patient 2Patient 3Patient 4Patient 5Protein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueDermatological diseases and conditions1.25E−04 to 3.17E−25Inflammatory response4.02E−03 to 1.91E−10Inflammatory response3.49E−04 to 9.03E−20Metabolic disease2.52E−04 to 1.54E−16Metabolic disease2.69E−03 to 1.27E−14Organismal injury and abnormalities2.03E−04 to 3.17E−25Organismal injury and abnormalities4.02E−03 to 1.91E−10Organismal injury and abnormalities3.49E−04 to 9.03E−20Connective tissue disorders3.72E−04 to 6.67E−16Inflammatory response2.55E−03 to 2.94E−14Metabolic disease1.89E−04 to 3.65E−23Hematological disease3.44E−03 to 3.53E−10Metabolic disease3.18E−04 to 7.41E−18Inflammatory disease5.16E−04 to 6.67E−16Hematological disease2.32E−03 to 2.21E−13Inflammatory response1.87E−04 to 1.24E−21Immunological disease3.44E−03 to 3.53E−10Neurological disease2.91E−04 to 6.16E−15Inflammatory response5.16E−04 to 6.67E−16Immunological disease1.95E−03 to 2.21E−13Neurological disease2.03E−04 to 1.37E−21Inflammatory disease2.94E−03 to 3.53E−10Psychological disorders2.55E−04 to 6.16E−15Organismal injury and abnormalities5.16E−04 to 6.67E−16Inflammatory disease2.55E−03 to 2.21E−13Table 6Top diseases and bio functions---physiological system development and functionPatient 1Patient 2Patient 3Patient 4Patient 5Protein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueProtein*P* valueImmune cell trafficking1.23E−04 to 3.97E−15Immune cell trafficking4.02E−03 to 1.33E−08Immune cell trafficking3.34E−04 to 2.69E−16Immune cell trafficking5.24E−04 to 2.61E−13Immune cell trafficking2.48E−03 to 2.24E−11Hematological system development and function2.01E−04 to 1.33E−13Hematological system development and function4.02E−03 to 5.37E−07Hematological system development and function3.34E−04 to 1.79E−12Hematological system development and function5.24E−04 to 4.87E−12Hematological system development and function2.55E−03 to 1.31E−09Cardiovascular system development and function1.66E−04 to 1.20E−11Humoral immune response2.42E−03 to 2.83E−06Tissue morphology3.21E−04 to 5.10E−10Cardiovascular system development and function5.24E−04 to 1.56E−10Organismal development1.88E−03 to 2.65E−07Organismal development1.66E−04 to 5.69E−11Organismal development4.02E−03 to 3.65E−05Organismal development2.62E−04 to 5.04E−09Organismal development4.95E−04 to 2.22E−10Humoral immune response9.19E−04 to 2.78E−07Humoral immune response6.88E−05 to 2.84E−10Lymphoid tissue structure and development3.90E−03 to 4.99E−05Organismal survival3.81E−06 to 8.49E−09Organismal survival1.89E−05 to 1.27E−08Tissue morphology2.27E−03 to 4.15E-07

Discussion {#Sec12}
==========

The current pilot study identifies ipsilateral changes in the tear fluid proteome of patients with unilateral AAU. Accordingly, Schirmer's test sampling of tear fluid potentially represents an adjuvant non-invasive approach to investigate the pathophysiological pathways in AAU.

For all patients, IPA identified the LXR/RXR and FXR/RXR pathways among the top canonical pathways affected. LXRs have predominantly been linked to regulation of lipid metabolism, but there is also mounting evidence of an anti-inflammatory role \[[@CR9]\]. LXRs modulate the immune response in lipopolysaccharide-activated macrophages by inhibiting expression of inflammatory mediators, including IL6 \[[@CR10]\]. LXR activation has also been associated with inhibition of the nuclear transcription factor-κB (NF-κB) \[[@CR11]\], which is a major transcription factor in the regulation of immune responses. In rats, inhibition of NF-κB ameliorated anterior uveitis in experimental autoimmune uveitis (EAU) \[[@CR12]\]. Furthermore, in a mouse model of EAU, a synthetic LXR agonist reduced ocular inflammation \[[@CR13]\]. The authors of the latter study suggested that LXR agonists had potential for becoming a therapeutic option for uveitis patients. LXRs were expressed in the native rat corneal epithelium and stroma in a rat model of inflammatory corneal angiogenesis \[[@CR14]\]. Following induction of inflammatory corneal angiogenesis, LXR expression temporarily decreased in the corneal epithelium, while removal of the inflammatory stimulus (corneal suture) was associated with activation of the LXR/RXR pathway and resolution of inflammation. Consequently, the authors suggested that LXR/RXR pathway activation could contribute to resolution of corneal inflammation. To our knowledge, the FXR/RXR pathway has not been directly linked to the pathogenesis of uveitis. In a study on endotoxin-induced uveitis in rats, however, the FXR antagonist guggulsterone suppressed ocular inflammation \[[@CR15]\]. The authors related this effect to the inhibition of NF-κB by guggulsterone. Ultimately, engagement of the LXR/RXR and FXR/RXR pathways in the current study indicates that signs of AAU-associated inflammation are detectable in ipsilateral tear fluid samples.

In the current study, IPA determined that the changes to the tear proteome in AAU were associated with an inflammatory process (i.e., *inflammatory response* and *immune cell trafficking* were among the *top diseases and bio functions*). The upstream analysis by IPA further underscored the inflammatory tear profile by identifying TNF and IL6 among the top upstream regulators in four of the five patients. The role of TNF in the pathogenesis of uveitis has been well-established in animal studies \[[@CR16], [@CR17]\], and the concentration of TNF was also raised in the aqueous humor of patients with uveitis \[[@CR18]\]. Most importantly, the essential role of TNF in uveitis has been confirmed by the recent success of employing the TNF-inhibitor adalimumab in the treatment of non-infectious uveitis \[[@CR19], [@CR20]\]. IL6 promotes the differentiation of CD4+ T-helper (Th) cells into Th17 cells, thereby contributing to the pathogenesis of autoimmune diseases \[[@CR21]\]. In uveitis, IL6 has been proposed to be especially important in HLA-B27 positive cases \[[@CR22]\]. The latter study also reported a higher concentration of IL6 in the aqueous humor of HLA-B27 positive uveitis patients compared to patients with Vogt-Koyanagi-Harada disease, sarcoidosis, or idiopathic granulomatous uveitis. This is in line with our study, in which IPA identified IL6 as an upstream regulator in the two HLA-B27 positive patients.

We found a significantly higher level of APOBEC3A, a DNA cytidine deaminase, in tear fluid of the diseased eye relative to the healthy control. Interferon, a regulating cytokine in autoimmune uveitis \[[@CR23]\], can induce APOBEC3A in monocytes. This enables deamination of foreign double-stranded DNA and inhibits replication of retroviruses and retrotransposons \[[@CR24]\]. In this way, APOBEC3A partakes in the innate immune system, and its increase in tear fluid from AAU eyes indicates local disease activity.

The level of TGM2 was reduced in tear fluid from the diseased eye. This is contradictory to a study on endotoxin-induced uveitis, in which the level of TGM2 was increased in aqueous humor \[[@CR25]\]. In agreement with our results, however, studies on Crohn's disease patients have reported an inverse relationship between TGM2 and disease activity \[[@CR26]\].

In total, 242 unique proteins were identified in the tear fluid samples. Only 32 proteins, however, were identified in all patients. The highest number of matching tear fluid proteins was seen in the three youngest patients that also had the shortest disease duration. On the other hand, HLA-B27 status was not obviously related to the number of matching tear fluid proteins. Nevertheless, as the anterior chamber cytokine profile differs between HLA-B27 positive and negative patients, the heterogeneity in HLA-B27 status might have contributed to the relative lack of matching proteins between patients in the current study.

In our study, tear fluid proteins were identified using a single Schirmer's test strip in each patient. Previous studies have reported a higher number of identified proteins when pooling tear fluid samples from multiple patients \[[@CR5]\]. Although proteomics is useful as a screening method for AAU biomarkers, the method has limited sensitivity for low-concentration proteins. Alternative methods, including enzyme-linked immunosorbent assay, are more suitable for detecting proteins at low concentrations. Accordingly, restricted sensitivity may have contributed to the rather poor correspondence of tear fluid proteins between the patients in the current study. Conclusively, we believe that failure to identify certain proteins across all patients in the present study should not lead to the exclusion of these as potential biomarkers.

Serpent family A member 3 (SERPINA3), also known as serine protease inhibitor 3 (SPI-3), was more than 14-fold elevated in tear fluid from the diseased eye in one patient, despite disease duration of only a single day. In addition, this protein was mildly elevated in two other patients. SERPINA3, also referred to as SPI-3, is normally found in the aqueous humor \[[@CR27]\], but it is also part of the acute phase response. In endotoxin-induced uveitis in rats following lipopolysaccharide injection, SERPINA3 mRNA in epithelial cells of the iris and ciliary body was rapidly upregulated as part of the initial inflammatory response \[[@CR28]\]. Yet another potential biomarker protein was increased in tear fluid from the diseased eye in three patients: orosomucoid 2 (ORM2), also known as alpha-1-acid glycoprotein. Similar to SERPINA3, ORM2 is an acute phase response protein. In a previous study, serum levels of ORM2 were increased in moderate and severe idiopathic AAU \[[@CR29]\]. Furthermore, in the latter study, ORM2 levels correlated with disease severity and returned to normal following resolution.

In conclusion, unilateral AAU induces inflammation-associated changes in the ipsilateral tear fluid proteome; in a clinical setting, Schirmer's strips can be used to collect tear samples for proteomics. The inflammation-associated LXR/RXR was among the top canonical pathways affected. Further studies are necessary to determine whether APOBEC3A, SERPINA3, and ORM2 are potential AAU biomarkers.
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